DK3385395T3 - Fremgangsmåder til behandling af cancerpatienter med farnesyltransferase-inhibitorer - Google Patents

Fremgangsmåder til behandling af cancerpatienter med farnesyltransferase-inhibitorer Download PDF

Info

Publication number
DK3385395T3
DK3385395T3 DK18173134.0T DK18173134T DK3385395T3 DK 3385395 T3 DK3385395 T3 DK 3385395T3 DK 18173134 T DK18173134 T DK 18173134T DK 3385395 T3 DK3385395 T3 DK 3385395T3
Authority
DK
Denmark
Prior art keywords
farcyl
methods
treating cancer
cancer patients
transferase inhibitors
Prior art date
Application number
DK18173134.0T
Other languages
Danish (da)
English (en)
Inventor
Antonio Gualberto
Catherine Rose Scholz
Original Assignee
Kura Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kura Oncology Inc filed Critical Kura Oncology Inc
Application granted granted Critical
Publication of DK3385395T3 publication Critical patent/DK3385395T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK18173134.0T 2015-08-17 2016-08-16 Fremgangsmåder til behandling af cancerpatienter med farnesyltransferase-inhibitorer DK3385395T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562206194P 2015-08-17 2015-08-17
US201562218927P 2015-09-15 2015-09-15
US201562241019P 2015-10-13 2015-10-13
US201662310582P 2016-03-18 2016-03-18
US201662372662P 2016-08-09 2016-08-09
EP16757791.5A EP3277842B9 (en) 2015-08-17 2016-08-16 Methods of treating cancer patients with farnesyl transferase inhibitors

Publications (1)

Publication Number Publication Date
DK3385395T3 true DK3385395T3 (da) 2020-04-20

Family

ID=56802700

Family Applications (3)

Application Number Title Priority Date Filing Date
DK16757791.5T DK3277842T5 (da) 2015-08-17 2016-08-16 Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer
DK19210527.8T DK3640345T3 (da) 2015-08-17 2016-08-16 Fremgangsmåder til at behandle kræftpatienter med farnesyltransferaseinhibitorer
DK18173134.0T DK3385395T3 (da) 2015-08-17 2016-08-16 Fremgangsmåder til behandling af cancerpatienter med farnesyltransferase-inhibitorer

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK16757791.5T DK3277842T5 (da) 2015-08-17 2016-08-16 Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer
DK19210527.8T DK3640345T3 (da) 2015-08-17 2016-08-16 Fremgangsmåder til at behandle kræftpatienter med farnesyltransferaseinhibitorer

Country Status (28)

Country Link
US (7) US10471055B2 (ja)
EP (4) EP3385395B9 (ja)
JP (4) JP6630742B2 (ja)
KR (4) KR102125496B1 (ja)
CN (5) CN114107497A (ja)
AU (3) AU2016308564B2 (ja)
CA (1) CA2985123C (ja)
CY (3) CY1122037T1 (ja)
DK (3) DK3277842T5 (ja)
EA (1) EA201890512A1 (ja)
ES (3) ES2901506T3 (ja)
HK (1) HK1254087A1 (ja)
HR (3) HRP20211976T1 (ja)
HU (3) HUE044698T2 (ja)
IL (1) IL257547B (ja)
LT (3) LT3277842T (ja)
MX (1) MX2018001769A (ja)
MY (1) MY195484A (ja)
NZ (1) NZ736853A (ja)
PH (1) PH12018500322A1 (ja)
PL (3) PL3277842T3 (ja)
PT (3) PT3385395T (ja)
RS (3) RS59158B9 (ja)
SG (1) SG10202101740QA (ja)
SI (3) SI3640345T1 (ja)
TW (3) TW202129012A (ja)
WO (1) WO2017031101A1 (ja)
ZA (2) ZA201801047B (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3385395T (pt) 2015-08-17 2020-05-06 Kura Oncology Inc Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
MX2019005065A (es) * 2016-11-03 2019-08-21 Kura Oncology Inc Metodos de tratamiento de pacientes con cancer con inhibidores de farnesiltransferasa.
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
KR20200051601A (ko) * 2017-08-07 2020-05-13 쿠라 온콜로지, 인크. 파르네실전달효소 억제제를 이용하여 암을 치료하는 방법
WO2019113269A1 (en) * 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
CN113286591A (zh) * 2018-11-01 2021-08-20 库拉肿瘤学公司 用法尼基转移酶抑制剂治疗癌症的方法
US20220071941A1 (en) * 2018-12-21 2022-03-10 Kura Oncology, Inc. Therapies for squamous cell carcinomas
CN110656172A (zh) * 2019-01-14 2020-01-07 南方医科大学珠江医院 一种预测小细胞肺癌对ep化疗方案敏感性的分子标志物及试剂盒
WO2020190604A1 (en) * 2019-03-15 2020-09-24 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
EP3942097A4 (en) * 2019-03-22 2024-03-27 Univ California CHMP2A AS A REGULATOR OF NATURAL KILLER CELL-MEDIATED ACTIVITY
WO2020205486A1 (en) * 2019-03-29 2020-10-08 Kura Oncology, Inc. Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
CN110241461A (zh) * 2019-06-24 2019-09-17 厦门大学 一种构建人nk细胞免疫球蛋白样受体文库的多重pcr引物和方法
CN111097039B (zh) * 2020-01-16 2020-11-06 南京医科大学 Ras相关蛋白2的制药用途
CN111088349B (zh) * 2020-02-14 2023-04-28 深圳市宝安区妇幼保健院 Kir3dl1基因分型引物组及其应用
EP4146346A1 (en) * 2020-05-08 2023-03-15 Cardiff Oncology, Inc. Methods of monitoring kras mutations
CN111863126B (zh) * 2020-05-28 2024-03-26 上海市生物医药技术研究院 构建结直肠肿瘤状态评估模型的方法及应用
US20240058321A1 (en) * 2021-11-02 2024-02-22 Semmelweis Egyetem Farnesyl-transferase inhibitors and kras inhibitors for treating kras mutant cancers
CN114045339B (zh) * 2021-11-05 2022-06-28 山东第一医科大学附属省立医院(山东省立医院) 铁死亡相关基因在弥漫大b细胞淋巴瘤预后评估中的应用
WO2023242104A1 (en) * 2022-06-13 2023-12-21 KHR Biotec GmbH Diaminoacridine derivatives as inhibitors of ras
WO2023242097A1 (en) * 2022-06-13 2023-12-21 KHR Biotec GmbH Mitoxanthrone derivatives as ras inhibitors

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US5693517A (en) 1987-06-17 1997-12-02 Roche Molecular Systems, Inc. Reagents and methods for coupled high temperature reverse transcription and polymerase chain reactions
US5310652A (en) 1986-08-22 1994-05-10 Hoffman-La Roche Inc. Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription
US5561058A (en) 1986-08-22 1996-10-01 Hoffmann-La Roche Inc. Methods for coupled high temperatures reverse transcription and polymerase chain reactions
CA1340843C (en) 1987-07-31 1999-12-07 J. Lawrence Burg Selective amplification of target polynucleotide sequences
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5976851A (en) 1990-04-18 1999-11-02 Board Of Regents, The University Of Texas System Methods and compositions for the identification, characterization, and inhibition of farnesyl protein transferase
US5420245A (en) 1990-04-18 1995-05-30 Board Of Regents, The University Of Texas Tetrapeptide-based inhibitors of farnesyl transferase
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5702885A (en) 1990-06-27 1997-12-30 The Blood Center Research Foundation, Inc. Method for HLA typing
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
ZA918965B (en) 1990-11-13 1992-08-26 Siska Diagnostics Inc Nucleic acid amplification by two-enzyme,self-sustained sequence replication
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5238922A (en) 1991-09-30 1993-08-24 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
EP0631635B1 (en) 1992-03-04 2001-09-12 The Regents Of The University Of California Comparative genomic hybridization (cgh)
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5686472A (en) 1992-10-29 1997-11-11 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5504212A (en) 1992-10-29 1996-04-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
EP0763537A3 (en) 1993-05-14 1997-10-22 Genentech Inc Non-peptides farnesyl transfer inhibitors
US5602098A (en) 1993-05-18 1997-02-11 University Of Pittsburgh Inhibition of farnesyltransferase
US5965539A (en) 1993-05-18 1999-10-12 Univeristy Of Pittsburgh Inhibitors of prenyl transferases
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5721236A (en) 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5523430A (en) 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
FR2721021B1 (fr) 1994-06-10 1996-07-12 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnésyl transférase, leur préparation et les compositions pharmaceutique qui les contiennent.
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5491063A (en) 1994-09-01 1996-02-13 Hoffmann-La Roche Inc. Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
US5661161A (en) 1994-09-29 1997-08-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5585359A (en) 1994-09-29 1996-12-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5491164A (en) 1994-09-29 1996-02-13 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5571673A (en) 1994-11-23 1996-11-05 Hoffmann-La Roche Inc. Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
FR2729390A1 (fr) 1995-01-18 1996-07-19 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2730491B1 (fr) 1995-02-09 1997-03-14 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
US5684013A (en) 1995-03-24 1997-11-04 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5700806A (en) 1995-03-24 1997-12-23 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5856326A (en) 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5578629A (en) 1995-03-29 1996-11-26 Merck & Co., Inc. Benzamide-containing inhibitors of farnesyl-protein transferase
US5534537A (en) 1995-03-29 1996-07-09 Merck & Co., Inc. Prodrugs of inhibitors of farnesyl-protein transferase
US5972984A (en) 1995-06-06 1999-10-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5756528A (en) 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0835101B1 (en) 1995-06-27 2004-06-09 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
FR2736641B1 (fr) 1995-07-10 1997-08-22 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2736638B1 (fr) 1995-07-12 1997-08-22 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
TR199800825T2 (xx) 1995-12-08 1998-08-21 Janssen Pharmaceutica N.V. Farnesil protein transferini inhibe eden (imidazol-5-il) metil-2-kinolinon t�revleri.
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US5968965A (en) 1996-01-30 1999-10-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US5891889A (en) 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0904080A4 (en) 1996-04-03 2001-08-01 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
US5852010A (en) 1996-04-03 1998-12-22 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5880140A (en) 1996-04-03 1999-03-09 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5965578A (en) 1996-04-03 1999-10-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5939557A (en) 1996-04-03 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5780492A (en) 1996-04-03 1998-07-14 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5869682A (en) 1996-04-03 1999-02-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU714560B2 (en) 1996-04-15 2000-01-06 Trustees Of The University Of Pennsylvania, The Sensitization of cells to radiation and chemotherapy
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5773455A (en) 1996-06-28 1998-06-30 Biomeasure, Incorporated Inhibitors of prenyl transferases
US5767274A (en) 1996-06-28 1998-06-16 Biomeasure, Incorporated Prenyl transferase inhibitors
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
KR100232231B1 (ko) 1996-09-13 2000-03-02 김영환 비휘발성 메모리 소자의 데이터 기입 장치 및 방법
US5777324A (en) 1996-09-19 1998-07-07 Sequenom, Inc. Method and apparatus for maldi analysis
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
US6024925A (en) 1997-01-23 2000-02-15 Sequenom, Inc. Systems and methods for preparing low volume analyte array elements
US5972966A (en) 1996-12-05 1999-10-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0946565B1 (en) 1996-12-20 2003-10-15 Tovarischestvo S Ogranichennoi Otvetstvennostju "Tabifarm" Method and device for production of lyophilized hydrochloride-1ss, 10ss-epoxy-13-dimethylamino-guaia-3(4)-en-6,12-olide
US6197350B1 (en) 1996-12-20 2001-03-06 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
RU2205831C2 (ru) * 1997-04-25 2003-06-10 Янссен Фармацевтика Н.В. Хиназолиноны, ингибирующие фарнезилтрансферазу
ATE222104T1 (de) 1997-06-02 2002-08-15 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen
HUP0100221A3 (en) 1998-01-16 2002-11-28 Takeda Pharmaceutical Sustained release compositions, process for producing the same and utilization thereof
WO1999045712A1 (en) 1998-03-05 1999-09-10 Formula One Administration Limited Data communication system
US6303654B1 (en) 1998-03-12 2001-10-16 Wisconsin Alumni Research Foundation Acyclic monoterpenoid derivatives
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6723564B2 (en) 1998-05-07 2004-04-20 Sequenom, Inc. IR MALDI mass spectrometry of nucleic acids using liquid matrices
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6104028A (en) 1998-05-29 2000-08-15 Genetrace Systems Inc. Volatile matrices for matrix-assisted laser desorption/ionization mass spectrometry
WO2000001691A1 (en) 1998-07-01 2000-01-13 Merck & Co., Inc. Process for making farnesyl-protein transferase inhibitors
TR200003882T2 (tr) 1998-07-06 2001-06-21 Janssen Pharmaceutica N.V. Artropatilerin tedavisi için farnesil protein transferaz inhibitörleri.
ATE238811T1 (de) 1998-07-06 2003-05-15 Janssen Pharmaceutica Nv Inhibitoren von farnesylprotein-transferase mit radiosensibilisierenden eigenschaften
CA2341690C (en) 1998-08-27 2007-04-17 Pfizer Products Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
ES2237125T3 (es) 1998-08-27 2005-07-16 Pfizer Products Inc. Derivados de quinolin-2-ona utiles como agentes anticancerigenos.
US6927024B2 (en) 1998-11-30 2005-08-09 Genentech, Inc. PCR assay
PT1140935E (pt) 1998-12-23 2003-10-31 Janssen Pharmaceutica Nv Derivados da quinolina 1,2-ciclizada
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20040157882A1 (en) 1999-11-30 2004-08-12 End David William Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation
WO2001042507A1 (en) 1999-12-09 2001-06-14 Advanced Research & Technology Institute Fluorescent in situ rt-pcr
US6670124B1 (en) 1999-12-20 2003-12-30 Stemcyte, Inc. High throughput methods of HLA typing
JP5491681B2 (ja) 2000-02-04 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤
JP2003523381A (ja) 2000-02-24 2003-08-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 投与レジメン
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
DK1339407T3 (da) 2000-11-28 2006-08-14 Janssen Pharmaceutica Nv Farnesylproteintransferaseinhibitorer til behandling af inflammatorisk tarmsygdom
WO2002064142A1 (en) 2001-02-15 2002-08-22 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with antiestrogen agents
PT2269603E (pt) * 2001-02-19 2015-09-09 Novartis Ag Tratamento de tumores da mama com um derivado de rapamicina em combinação com exemestano
CN100523216C (zh) 2001-03-02 2009-08-05 匹兹堡大学 Pcr方法
CZ300622B6 (cs) 2001-03-12 2009-07-01 Janssen Pharmaceutica N. V. Zpusob prípravy 4-(3-chlorfenyl)-6-[(4-chlorfenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-chinolinonu
WO2002085364A1 (en) 2001-04-25 2002-10-31 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating cachexia
CN101426928A (zh) * 2001-10-30 2009-05-06 奥索临床诊断有限公司 评价和治疗白血病的方法
BR0206251A (pt) 2001-10-30 2004-06-15 Ortho Clinical Diagnostics Inc Métodos para avaliar e tratar leucemia
WO2003080058A1 (en) 2002-03-22 2003-10-02 Janssen Pharmaceutica. N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
EP1685149A4 (en) 2003-10-22 2007-03-28 Pel Freez Clinical Systems Inc PRIMER, METHOD AND KITS FOR DETECTING ALL KILLER-CELL IMMUNOGLOBULIN-LIKE RECEPTOR
EP1536021A1 (en) 2003-11-27 2005-06-01 Consortium National de Recherche en Genomique (CNRG) Method for HLA typing
US7122799B2 (en) 2003-12-18 2006-10-17 Palo Alto Research Center Incorporated LED or laser enabled real-time PCR system and spectrophotometer
WO2005105784A1 (en) 2004-05-03 2005-11-10 Janssen Pharmaceutica N.V. Diastereoselective synthesis process for the preparation of imidazole compounds
ES2346986T3 (es) 2004-05-03 2010-10-22 Janssen Pharmaceutica Nv Proceso de sintesis diastereoselectiva con 6-bromo-4-(3-clorofenil)-2-methoxi-quinolina.
DE602005007604D1 (de) 2004-05-03 2008-07-31 Janssen Pharmaceutica Nv Diastereoselektive addition von lithiiertem n-methylimidazol an sulfinimine
PT1815247E (pt) 2004-11-05 2013-04-23 Janssen Pharmaceutica Nv Uso terapêutico de inibidores de farnesiltransferase e métodos para monitorizar a eficácia do mesmo
US20080051379A1 (en) 2004-12-01 2008-02-28 Trustees Of Boston University Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms
WO2007041067A2 (en) 2005-09-29 2007-04-12 Children's Hospital & Research Center At Oakland Methods and compositions for kir genotyping
WO2007110709A2 (en) 2005-10-14 2007-10-04 Janssen Pharmaceutica, N.V. Formulations of tipifarnib for intravenous administration
WO2009051672A2 (en) 2007-10-12 2009-04-23 St. Jude Children's Research Hospital Natural killer immunoglobulin-like receptor (kir) assay
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
MX2010013281A (es) 2008-06-03 2010-12-21 Janssen Pharmaceutica Nv Peptido mimetico de trombopoyetina para prevenir trastornos hematologicos asociados con el tratamiento del cancer.
US8771951B2 (en) 2009-11-16 2014-07-08 Genomics Usa, Inc. Methods for PCR and HLA typing using raw blood
CN103328971B (zh) * 2010-07-28 2016-09-28 维里德克斯有限责任公司 急性髓细胞性白血病应答法尼基转移酶抑制剂治疗的测定方法
US11559540B2 (en) 2010-07-28 2023-01-24 Janssen Pharmaceutica Nv Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
BR112013008511A2 (pt) 2010-10-06 2017-07-25 St Jude Childrens Res Hospital tipagem com base em determinantes moleculares de alelos de kir e de ligantes de kir
WO2014160130A1 (en) * 2013-03-13 2014-10-02 Oncoceutics, Inc. Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
WO2015144184A1 (en) 2014-03-26 2015-10-01 University Of Copenhagen Use of timp-1 as a biomarker in the egf-receptor inhibitor treatment of metastatic colorectal cancer
CA2946759A1 (en) * 2014-04-25 2015-10-29 Memorial Sloan-Kettering Cancer Center Treatment of h-ras-driven tumors
PT3385395T (pt) * 2015-08-17 2020-05-06 Kura Oncology Inc Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
MX2019005065A (es) 2016-11-03 2019-08-21 Kura Oncology Inc Metodos de tratamiento de pacientes con cancer con inhibidores de farnesiltransferasa.

Also Published As

Publication number Publication date
EP3640345B9 (en) 2021-11-24
CN111214658A (zh) 2020-06-02
TWI621437B (zh) 2018-04-21
CN111214658B (zh) 2022-01-11
US9707221B2 (en) 2017-07-18
CY1122037T1 (el) 2020-10-14
TW201821619A (zh) 2018-06-16
SI3277842T1 (sl) 2019-11-29
PH12018500322A1 (en) 2018-09-10
TW201717951A (zh) 2017-06-01
AU2018203045A1 (en) 2018-05-17
DK3640345T3 (da) 2022-01-03
US10335404B2 (en) 2019-07-02
DK3277842T5 (da) 2020-08-31
NZ736853A (en) 2019-09-27
EP3385395A1 (en) 2018-10-10
TW202129012A (zh) 2021-08-01
ZA201900858B (en) 2023-04-26
US20180280376A1 (en) 2018-10-04
JP2018519264A (ja) 2018-07-19
HRP20200659T1 (hr) 2020-08-07
KR101885361B1 (ko) 2018-08-06
HRP20191424T1 (hr) 2019-11-15
CN114306604A (zh) 2022-04-12
HUE049620T2 (hu) 2020-09-28
US20170304291A1 (en) 2017-10-26
KR102125496B1 (ko) 2020-06-23
KR20210048600A (ko) 2021-05-03
CA2985123A1 (en) 2017-02-23
HRP20191424T2 (hr) 2021-06-25
RS60149B1 (sr) 2020-05-29
ES2901506T3 (es) 2022-03-22
US10022364B2 (en) 2018-07-17
EP3277842B9 (en) 2020-01-15
US20170071931A1 (en) 2017-03-16
KR20180089527A (ko) 2018-08-08
IL257547A (en) 2018-04-30
CY1123067T1 (el) 2021-10-29
EP3385395B9 (en) 2020-05-20
MY195484A (en) 2023-01-26
EA201890512A1 (ru) 2018-09-28
US20180092903A1 (en) 2018-04-05
SI3640345T1 (sl) 2022-01-31
RS60149B9 (sr) 2021-02-26
US10471055B2 (en) 2019-11-12
EP3277842A1 (en) 2018-02-07
JP6630742B2 (ja) 2020-01-15
AU2018203045C1 (en) 2021-02-11
HRP20211976T1 (hr) 2022-03-18
AU2020281160B2 (en) 2023-06-22
AU2016308564A1 (en) 2017-11-23
CA2985123C (en) 2021-04-13
EP3640345A1 (en) 2020-04-22
PL3385395T3 (pl) 2020-07-13
AU2018203045B2 (en) 2020-11-12
JP2024037857A (ja) 2024-03-19
US11207314B2 (en) 2021-12-28
HUE057306T2 (hu) 2022-04-28
ES2741782T3 (es) 2020-02-12
EP3385395B1 (en) 2020-01-29
US20170051356A1 (en) 2017-02-23
LT3640345T (lt) 2022-01-10
HUE044698T2 (hu) 2019-11-28
CN107787373A (zh) 2018-03-09
SI3385395T1 (sl) 2020-07-31
RS59158B1 (sr) 2019-10-31
AU2016308564B2 (en) 2018-04-26
US10292979B2 (en) 2019-05-21
ZA201801047B (en) 2019-04-24
LT3277842T (lt) 2019-10-25
PT3640345T (pt) 2021-12-29
ES2787073T3 (es) 2020-10-14
US20180193329A1 (en) 2018-07-12
CY1124879T1 (el) 2022-11-25
AU2020281160A1 (en) 2021-01-07
MX2018001769A (es) 2018-08-15
HK1254087A1 (zh) 2019-07-12
CN107787373B (zh) 2021-11-26
KR20200074268A (ko) 2020-06-24
PT3277842T (pt) 2019-09-05
RS59158B9 (sr) 2020-09-30
IL257547B (en) 2022-05-01
JP2022058680A (ja) 2022-04-12
US20230089412A1 (en) 2023-03-23
PL3640345T3 (pl) 2022-02-07
KR102246710B1 (ko) 2021-04-30
SG10202101740QA (en) 2021-04-29
DK3277842T3 (da) 2019-08-26
PL3277842T3 (pl) 2019-12-31
PT3385395T (pt) 2020-05-06
BR112018003091A2 (pt) 2018-09-25
EP3277842B1 (en) 2019-07-10
WO2017031101A1 (en) 2017-02-23
CN114107497A (zh) 2022-03-01
CN108371711A (zh) 2018-08-07
EP3995589A1 (en) 2022-05-11
LT3385395T (lt) 2020-05-11
KR20170138532A (ko) 2017-12-15
TWI710642B (zh) 2020-11-21
JP7323393B2 (ja) 2023-08-08
RS62709B1 (sr) 2022-01-31
EP3640345B1 (en) 2021-10-06
JP2020002164A (ja) 2020-01-09

Similar Documents

Publication Publication Date Title
DK3385395T3 (da) Fremgangsmåder til behandling af cancerpatienter med farnesyltransferase-inhibitorer
DK3331915T3 (da) Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere
DK3377516T3 (da) Sammensætning til behandling af cancer
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3122358T3 (da) Kombinationer af fgfr- og cmet-hæmmere til cancerbehandling
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3303339T3 (da) Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
DK3099298T3 (da) Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner
DK3371165T3 (da) Btk-inhibitor til anvendelse til behandling af kræft
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
DK3307267T3 (da) Behandling af multipel sklerose
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
DK3134124T3 (da) Igf-1r-antistof-lægemiddel-konjugat og dens anvendelse til behandling af kræft
DK3200748T3 (da) Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted
DK3349731T3 (da) Kombination af topoisomerase-i-inhibitorer med immunoterapi til behandlingen af kræft
DK3364975T3 (da) Kombination af trazodon og gabapentin til behandling af smerter
DK3271320T3 (da) Sammensætninger til behandling af fibrose og fibroserelaterede tilstande